PPARG and cancer: While synthetic thiazolidinedione-class PPARγ agonists were initially used as anti-diabetic agents, PPARγ ligands have more recently been examined as potential therapeutic or chemoprevention targets for dermatologic conditions, including cancer and inflammatory dermatoses [1,5].